Macrocyclic inhibitors of DYRK1A
US12157741B2 · kind B2 · utility
0Cited by
0References
33Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 19, 2019 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Dec 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/22
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are macrocyclic compounds that possess inhibitory activity against DYRK, TRK, TLK, and/or RET. Also disclosed are pharmaceutical compositions containing the compounds, methods of making the compounds, and methods of using the compounds to treat diseases and disorders that are characterized or mediated by aberrant DYRK, TRK, TLK, and/or RET activity such as cancer, neurodegenerative disorders and genetic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.